90.22 0.00 (0.00%)
After hours: 4:35PM EDT
|Bid||80.15 x 800|
|Ask||95.00 x 900|
|Day's Range||89.65 - 93.50|
|52 Week Range||71.90 - 106.27|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||18.50|
|Earnings Date||Nov 6, 2018|
|Forward Dividend & Yield||1.52 (1.64%)|
|1y Target Est||99.48|
Investing.com - Healthcare fell out of favor Monday, weighed down by a slump in shares of Bristol-Myers Squibb and AmerisourceBergen.
Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether certain directors and officers of AmerisourceBergen Corporation (“Amerisource” or the “Company”) (ABC) breached their fiduciary duties to Amerisource and its shareholders. If you are a Amerisource shareholder, you are encouraged to contact Amber Eck at (619) 342-8000 or email@example.com for additional information.
NEW YORK, Oct. 16, 2018 -- Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Sanmina.
NEW YORK, Oct. 16, 2018 -- Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies..
Looking at AmerisourceBergen Corporation’s (NYSE:ABC) earnings update in June 2018, it seems that analyst forecasts are fairly optimistic, as a 34% increase in profits is expected in the upcoming year, Read More...
On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating the safety and efficacy of Biktarvy for treating HIV-1 infections in treatment-naive patients. The drug was found to be statistically non-inferior to a regimen of abacavir, dolutegravir, and lamivudine through 96 weeks of therapy.
NEW YORK , Oct. 4, 2018 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, is investigating whether certain directors ...
AmerisourceBergen Corporation (ABC) today announced that it plans to release its results for the Fourth Quarter Fiscal 2018 on Tuesday, November 6, 2018, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 6, 2018. No access code is required.
AmerisourceBergen, which is based in Chesterbrook, Pa., agreed to the settlement, announced on Monday, to resolve civil liability under the False Claims Act. The company, one of the largest U.S. drug wholesalers, said in a statement it has acknowledged some of its practices at the subsidiaries were inconsistent with AmerisourceBergen’s approach to corporate compliance. “Michael Mullen was not fired by AmerisourceBergen for being a whistleblower,” Lauren Esposito, a company spokeswoman, said in the statement.
AmerisourceBergen Corp, one of the largest U.S. drug wholesalers, will pay $625 million to resolve civil fraud charges over the sale of syringes containing drugs for cancer patients, double billing, and providing kickbacks to doctors. The settlement announced on Monday by the U.S. Department of Justice boosts AmerisourceBergen's total payout to $885 million over its repackaging and distribution of pre-filled syringes that were not approved by the U.S. Food and Drug Administration. In September 2017, the company's AmerisourceBergen Specialty Group unit pleaded guilty to a related misdemeanor, and paid $260 million of criminal fines and forfeitures.
WASHINGTON , Oct. 1, 2018 /PRNewswire/ -- Whistleblower Law Collaborative and Kellogg, Hansen, Todd, Figel & Frederick, P.L.L.C. report Michael Mullen , the former chief operating officer of a subsidiary ...
The settlement agreed to by AmerisourceBergen resolves charges tied to the improper repackaging of cancer drugs by a subsidiary.
AmerisourceBergen Corp. has agreed to pay $625 million for selling unapproved and adulterated drugs, including cancer drugs, New York Attorney General Barbara Underwood said in a statement on Monday. The payment will go to multiple states and the federal government, Underwood said. As part of the deal, an AmerisourceBergen unit pleaded guilty to illegally distributing misbranded drugs in September 2017, Underwood said.
NEW YORK, Sept. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
This article is intended for those of you who are at the beginning of your investing journey and want to learn about Return on Equity using a real-life example. ABCRead More...
Today we’re going to take a look at the well-established AmerisourceBergen Corporation (NYSE:ABC). The company’s stock saw significant share price volatility over the past couple of months on the NYSE,Read More...
Mr. Guttman has served as the company’s chief financial officer since May 2012, and was previously vice president and corporate controller since joining the company in 2002. Mr. Cleary was most recently group president, global commercialization services and animal health at AmerisourceBergen.
AmerisourceBergen Corporation (ABC) today announced that Tim G. Guttman, Executive Vice President and Chief Financial Officer, has decided to retire from the Company. James F. Cleary, Jr., Executive Vice President and Group President, Global Commercialization Services and Animal Health, will succeed Guttman as Executive Vice President and Chief Financial Officer.